Thursday, September 19, 2024
- Advertisement -spot_img

TAG

ACW

Actinogen’s Xanamem could slow Alzheimer’s progress, new biomarker trial reveals

A biomarker trial of Actinogen Medical’s (ASX: ACW) lead candidate Xanamem has been published in the peer-reviewed Journal of Alzheimer’s Disease, with results showing...

Latest news

- Advertisement -spot_img